The intestinal microbiota is central in the antibiotic resistance phenomenon. Nonetheless, the impact of antibiotics on the intestinal microbiota remains poorly described, mainly because of the lack of phenotypic characterization of the resistance mechanisms of intestinal bacteria. Here, we propose to study the impact of various beta-lactams regimens (ceftriaxone, piperacillin-tazobactam and ceftazidime-avibactam, with or without a colon-delivered charcoal-based adsorbent) the intestinal microbiota of healthy volunteers, leveraging fecal antibiotic concentrations, state-of-the-art metagenomic analysis (combining short and long reads), phenotypic characterization, in vitro evolutionary models and longitudinal data analysis. Altogether, BLA-IMPACT will help in bridging phenotypic and metagenomic data that are mandatory to understand how the intestinal microbiota evolved under antibiotic exposure.